1. Home
  2. TAK
  3. TAK News

Latest Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of) (TAK) News on November 17, 2024

Why this major drugmaker no longer has an ‘IT department’
TAK

Fortune

4 days ago

Why this major drugmaker no longer has an ‘IT department’

New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD
TAK

CNW Group

13 days ago

New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD

TAK

MT Newswires

18 days ago

HUTCHMED Earns $20 Million Milestone Payment After Takeda Reaches Over $200 Million in Fruquintinib Sales

TAK

MT Newswires

18 days ago

Takeda Pharmaceutical's Fiscal Q2 Core Earnings, Revenue Increase; Fiscal-Year Outlook Raised

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
TAK

GlobeNewswire

18 days ago

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook
TAK

Business Wire

18 days ago

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

What To Expect From Takeda Pharmaceutical Co Ltd (TSE:4502) Q2 2025 Earnings
TAK

GuruFocus.com

18 days ago

What To Expect From Takeda Pharmaceutical Co Ltd (TSE:4502) Q2 2025 Earnings

Takeda and BMC partner to decarbonise US healthcare sector
TAK

Pharmaceutical Technology

24 days ago

Takeda and BMC partner to decarbonise US healthcare sector

TAK

MT Newswires

24 days ago

Takeda Pharmaceutical, Boston Medical Center Team Up for Decarbonization Project

Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem
TAK

Business Wire

24 days ago

Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem

TAK

Leasing Life

a month ago

Deko and Shire Leasing partner to offer B2B leasing at checkout

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
TAK

Benzinga

a month ago

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

Strategic Moves in the Japanese Market: T. Rowe Price Japan Fund's Focus on Takeda Pharmaceutical
TAK

GuruFocus.com

a month ago

Strategic Moves in the Japanese Market: T. Rowe Price Japan Fund's Focus on Takeda Pharmaceutical

WAVE Life Sciences Ltd (WVE) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising ...
TAK

GuruFocus.com

a month ago

WAVE Life Sciences Ltd (WVE) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising ...

TAK

MT Newswires

a month ago

Takeda Forms Joint Venture With Astellas, Sumitomo Mitsui to Develop Early-Drug Discovery Programs in Japan

TAK or CTLT: Which Is the Better Value Stock Right Now?
TAK

Zacks

a month ago

TAK or CTLT: Which Is the Better Value Stock Right Now?

Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
TAK

Zacks

a month ago

Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?

Tempus Stock Up Following Collaboration Expansion in Oncology R&D
TAK

Zacks

2 months ago

Tempus Stock Up Following Collaboration Expansion in Oncology R&D

How Many Stocks Should You Own?
TAK

Zacks

2 months ago

How Many Stocks Should You Own?

Tempus AI expands oncology collaboration with Takeda
TAK

Pharmaceutical Technology

2 months ago

Tempus AI expands oncology collaboration with Takeda

TAK

MT Newswires

2 months ago

Tempus AI Expands Takeda Partnership to Support Cancer Drug Research

TAK

MT Newswires

2 months ago

Alvotech Starts Confirmatory Study for Biosimilar Candidate to Entyvio

The Zacks Analyst Blog Highlights Takeda Pharma, Naspers and Packaging Corp. of America
TAK

Zacks

2 months ago

The Zacks Analyst Blog Highlights Takeda Pharma, Naspers and Packaging Corp. of America

Takeda’s FRUZAQLA approved in Japan for advanced colorectal cancer
TAK

Pharmaceutical Technology

2 months ago

Takeda’s FRUZAQLA approved in Japan for advanced colorectal cancer

TAK

MT Newswires

2 months ago

Takeda Pharmaceutical Says Colorectal Cancer Drug Received Marketing Approval in Japan

Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
TAK

Business Wire

2 months ago

Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
TAK

GlobeNewswire

2 months ago

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

MHRA approves Takeda’s fruquintinib for metastatic colorectal cancer
TAK

Pharmaceutical Technology

2 months ago

MHRA approves Takeda’s fruquintinib for metastatic colorectal cancer

Takeda Pharmaceutical Company Limited (TAK): Hedge Funds Are Bullish On This Japanese Stock Now
TAK

Insider Monkey

2 months ago

Takeda Pharmaceutical Company Limited (TAK): Hedge Funds Are Bullish On This Japanese Stock Now

Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024
TAK

Business Wire

2 months ago

Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024

Lupin and Takeda to commercialise Vonoprazan in India
TAK

Pharmaceutical Technology

2 months ago

Lupin and Takeda to commercialise Vonoprazan in India

Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries
TAK

Business Wire

2 months ago

Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries

TAK vs. STVN: Which Stock Is the Better Value Option?
TAK

Zacks

2 months ago

TAK vs. STVN: Which Stock Is the Better Value Option?

Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?
TAK

Zacks

2 months ago

Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?

Vatroslav Mateljic Appointed General Manager of Takeda Canada
TAK

CNW Group

2 months ago

Vatroslav Mateljic Appointed General Manager of Takeda Canada

Buyout Firm GTCR Is in Advanced Talks to Acquire German Drugmaker Stada
TAK

Bloomberg

2 months ago

Buyout Firm GTCR Is in Advanced Talks to Acquire German Drugmaker Stada

Investors are waking up to Centessa’s sleepiness drug
TAK

BioPharma Dive

2 months ago

Investors are waking up to Centessa’s sleepiness drug

Takeda Pharmaceutical Company Limited (TAK): A Cheap Pharmaceutical Stock to Buy According to Short Sellers
TAK

Insider Monkey

3 months ago

Takeda Pharmaceutical Company Limited (TAK): A Cheap Pharmaceutical Stock to Buy According to Short Sellers

Takeda’s ADZYNMA gains EU approval for cTTP treatment
TAK

Pharmaceutical Technology

3 months ago

Takeda’s ADZYNMA gains EU approval for cTTP treatment

Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday?
TAK

Benzinga

3 months ago

Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday?

TAK

MT Newswires

3 months ago

Takeda Wins European Commission's Approval for Adzynma to Treat Blood Clotting Disorder

Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
TAK

Business Wire

3 months ago

Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Japan Fund That Beat 92% of Peers in 2024 Touts Seven & I, Orix
TAK

Bloomberg

3 months ago

Japan Fund That Beat 92% of Peers in 2024 Touts Seven & I, Orix

Japan’s Selloff Sank Global Markets. Why This Fund Manager Is Still Bullish.
TAK

Barrons.com

3 months ago

Japan’s Selloff Sank Global Markets. Why This Fund Manager Is Still Bullish.

TAK

MT Newswires

3 months ago

Update: Market Chatter: Takeda Pharmaceutical to Eliminate 1,000 US Jobs

TAK

MT Newswires

3 months ago

Market Chatter: Takeda Pharmaceutical to Eliminate 1,000 US Jobs

Takeda’s revenue climbs by 14.1% in Q1 FY2024
TAK

Pharmaceutical Technology

4 months ago

Takeda’s revenue climbs by 14.1% in Q1 FY2024

TAK

MT Newswires

4 months ago

Sector Update: Health Care Stocks Flat to Lower Premarket Wednesday

TAK

MT Newswires

4 months ago

Takeda Pharmaceutical Fiscal Q1 Earnings, Revenue Increase; Reaffirms Fiscal 2024 Guidance

Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline
TAK

Business Wire

4 months ago

Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline

TAK

MT Newswires

4 months ago

Dr. Reddy's Laboratories to Market Takeda's Acid-Reflux Medication in India

Shire Leasing accredited to deliver Growth Guarantee Scheme
TAK

Leasing Life

4 months ago

Shire Leasing accredited to deliver Growth Guarantee Scheme

Polpharma looks to challenge Takeda’s Entyvio in IBD
TAK

Pharmaceutical Technology

4 months ago

Polpharma looks to challenge Takeda’s Entyvio in IBD

TAK

MT Newswires

5 months ago

Bloomberg Video: Takeda To Keep Pushing for China Biotech Partnership

Takeda Announces New Assignments of Directors
TAK

Business Wire

5 months ago

Takeda Announces New Assignments of Directors

FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
TAK

Zacks

5 months ago

FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder

Takeda reports positive data from Phase IIb trial of ITP treatment
TAK

Clinical Trials Arena

5 months ago

Takeda reports positive data from Phase IIb trial of ITP treatment

EC approves Takeda’s Fruzaqla for metastatic colorectal cancer
TAK

Pharmaceutical Technology

5 months ago

EC approves Takeda’s Fruzaqla for metastatic colorectal cancer

TAK

MT Newswires

5 months ago

Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
TAK

Business Wire

5 months ago

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
TAK

Business Wire

5 months ago

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia

TAK

MT Newswires

5 months ago

Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
TAK

Business Wire

5 months ago

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
TAK

GlobeNewswire

5 months ago

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda

Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older
TAK

CNW Group

5 months ago

Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older

Takeda reports long-term data from Phase III CIDP treatment trial
TAK

Clinical Trials Arena

5 months ago

Takeda reports long-term data from Phase III CIDP treatment trial

OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies
TAK

Zacks

5 months ago

OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies

TAK

MT Newswires

5 months ago

Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP

Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
TAK

Business Wire

5 months ago

Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting

Takeda’s epilepsy drug misses the mark in two Phase III trials
TAK

Clinical Trials Arena

5 months ago

Takeda’s epilepsy drug misses the mark in two Phase III trials

TAK

MT Newswires

5 months ago

Ovid Seeks Distance From Epilepsy Drug After Takeda Reports Phase 3 Endpoints Missed -- Pre-Bell Shares Fall

Takeda drug for rare types of epilepsy misses goal in late-stage trial
TAK

BioPharma Dive

5 months ago

Takeda drug for rare types of epilepsy misses goal in late-stage trial

TAK

MT Newswires

5 months ago

Takeda Says Phase 3 Soticlestat Trials in Dravet, Lennox-Gastaut Syndromes Missed Primary Endpoints

Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
TAK

Business Wire

5 months ago

Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda signs option agreement with Ascentage for CML drug
TAK

Pharmaceutical Technology

5 months ago

Takeda signs option agreement with Ascentage for CML drug

TAK

MT Newswires

5 months ago

Takeda Signs Option Agreement with Ascentage to License Leukemia Drug

Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
TAK

Business Wire

5 months ago

Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)

Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing
TAK

BioPharma Dive

5 months ago

Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing

Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts
TAK

Business Wire

5 months ago

Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
TAK

Simply Wall St.

5 months ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North
TAK

AFP

5 months ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend
TAK

Simply Wall St.

5 months ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m
TAK

Simply Wall St.

5 months ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week
TAK

Barrons.com

5 months ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend
TAK

Simply Wall St.

5 months ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued
TAK

Simply Wall St.

5 months ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Should You Buy OVB Holding AG (ETR:O4B) For Its Upcoming Dividend?
TAK

Simply Wall St.

5 months ago

Should You Buy OVB Holding AG (ETR:O4B) For Its Upcoming Dividend?

TAK

MT Newswires

5 months ago

Takeda Pharmaceutical Unit Partners with HEALWELL AI for Real-World Evidence Analysis of Hereditary Angioedema

TAK

MT Newswires

5 months ago

Takeda Pharmaceutical, Pfizer Say Phase 3 Trial Assessing Blood Cancer Combination Therapy Met Co-Primary Endpoints

TAK

MT Newswires

5 months ago

Takeda Says Narcolepsy Drug Meets Main, Secondary Goals in Trial

Takeda and Pfizer report positive Phase III HD21 trial of ADCETRIS
TAK

Clinical Trials Arena

5 months ago

Takeda and Pfizer report positive Phase III HD21 trial of ADCETRIS

Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
TAK

Business Wire

5 months ago

Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo

Blackstone Is Considering the Sale of Alinamin Pharmaceutical, Sources Say
TAK

Bloomberg

5 months ago

Blackstone Is Considering the Sale of Alinamin Pharmaceutical, Sources Say

Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
TAK

Business Wire

6 months ago

Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma

TAK

MT Newswires

6 months ago

Takeda Pharmaceutical Says Recombinant ADAMTS13 Gets Approval Recommendation From European Medicines Agency's CHPM

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
TAK

Business Wire

6 months ago

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

TAK

MT Newswires

6 months ago

Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment

Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection
TAK

CNW Group

6 months ago

Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection

Takeda’s dengue vaccine obtains WHO prequalification
TAK

Pharmaceutical Technology

6 months ago

Takeda’s dengue vaccine obtains WHO prequalification

TAK

MT Newswires

6 months ago

Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification

Share on Social Networks: